€ 1.2 Million in EU Project Funding for Enzymicals
News Apr 28, 2015
Enzymicals is a consortium partner in three projects of the H2020-funding period. With these projects a total of € 1.2 million grants were procured for Enzymicals. The company thus has the opportunity to focus more on the scale-up and piloting of biocatalytic processes, on developing new products and on promoting young scientists. At the same time these projects strengthen the company’s international network.
An important project is the COSMOS project which will be running over 54 months. The aim of the project is to increase Europe's independence of imported coconut and palm kernel oils and fatty acids as well as castor oil. These are currently important sources of raw materials for the production of various fatty acids. The fatty acids are starting materials for the production of plastics, surfactants, detergents,lubricants and many others.
From robust indigenous oil plants oils are extracted which are more suitable for obtaining these fatty acids than e.g. Rapeseed oil. The project includes work on the cultivation of oil crops, on optimizing the composition and on increasing the yield of the pressed oils. Other tasks deal with the separation and purification of the fatty acids which are extracted from crude product. Further aspects are processes for producing the desired fatty acids and the recycling of waste materials from the oil crops and press cake. In the consortium 18 partners from 9 countries work together. The entire project is funded by the EU with € 10.8 million.
In the separation and purification of the fatty acids selective enzyme technology will be used. The task of Enzymicals is the upscaling and the piloting of the manufacturing process for lipases which are suitable for these processes.
In the CARBAZYMES project a total of € 9.3 million will be invested. Funding from the EU is € 8.3 million over four years. The international, multidisciplinary consortium consists of 14 companies and research centers in 5 countries.
In the chemical industry, there is a great need for robust, industrially useful biocatalysts for the formation of carbon bonds. The classical chemical reactions involve the use of hazardous substances and a high energy consumption. The use of enzymes has great potential to improve these processes both from an economic and from an environmental point of view. The aim of the CARBAZYMES project is the development and subsequent scale up to an industrial process for four pharmaceutical intermediates and three bulk chemicals.
In this project Enzymicals works on the process of manufacturing an intermediate for a frequently used drug. For this purpose unique enzymes produced by Enzymicals are tested, and the process will be increased up to the 100L scale.
Enzymicals is an industry partner in the innovative training network Marie Curie BIOCASCADES for European industrial doctorates (ITN Enzymicals AG 3 EID). In this Research Network seven universities and five industrial companies from five European countries are involved.
In total eleven ESRs (early stage researchers) will be dealing with the development of sustainable cascade reactions for the production of specific amines and amino alcohols. These are important intermediates for pharmaceutically active substances such as those used in drugs for emergency treatment of anaphylaxis (allergic shock) or in cough solvers. Enzymicals contributes here with a position for a young scientist and the provision of several workplaces for exchange scientists.
With all three projects Enzymicals highlights its positioning as a developer of industrially applicable biocatalytic processes in pilot scale.
Innovative ALS Therapy Startup Wins Golden Ticket Funding From AmgenNews
Amgen and LabCentral have announced that Kernal Biologics Inc. and QurAlis have won the Amgen Golden Ticket at LabCentral.READ MORE
Children With Congenital Zika Virus Infection Face Serious Challenges as They AgeNews
The report from the CDC is the first to describe the health and developmental effects of congenital Zika virus infection in children with microcephaly through 2 years of age.READ MORE